Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

JETREA® Selected for Single Technology Appraisal by UK’s NICE

Published: Monday, March 25, 2013
Last Updated: Monday, March 25, 2013
Bookmark and Share
The outcome of the STA is expected later in 2013.

ThromboGenics NV has announced that JETREA® (ocriplasmin) has been selected to receive a Single Technology Appraisal (STA) from the UK’s National Institute for Health and Clinical Excellence (NICE).

The outcome of the STA, in the form of NICE guidance, is expected later in 2013, following the launch of JETREA® in the UK.

The JETREA® European Marketing Authorization Application is currently under review by the European Medicines Agency.

A decision on European approval is expected in the first half of 2013.

JETREA® was recently approved by the U.S. Food and Drugs Administration for the treatment of symptomatic Vitreomacular Adhesion (VMA).

In March 2012, ThromboGenics has signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States.

The NICE STA process is designed to provide recommendations on the use of new medicines in the National Health Service (NHS).

The STA is specifically designed to appraise a single product with a single indication, and enables NICE to produce guidance soon after the technology is introduced in the UK. During the appraisal process, NICE seeks evidence from several sources.

ThromboGenics and its partner Alcon, will submit the principal evidence for the JETREA® STA shortly. This submission will be assessed by an Evidence Review Group (ERG), an external independent academic organization, which will produce a review of the evidence submission.

The STA also relies on information and evidence from clinical consultants, and NHS commissioning authorities as well as patient groups.

Dr Patrik De Haes, CEO at ThromboGenics, said: "We are delighted that the UK Department of Health has asked NICE to appraise JETREA® (ocriplasmin) for the treatment of vitreomacular traction. We strongly believe that JETREA® has the potential to dramatically change the treatment paradigm in the UK for this progressive sight threatening condition".

We plan to submit, along with our partner Alcon, our dossier for the STA shortly and look forward to working with NICE and all parties involved in the appraisal process.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ThromboGenics Appoints Dominique Vanfleteren as New CFO
Dominique has over 25 years of experience in senior finance, operational, control and reporting roles.
Saturday, January 17, 2015
ThromboGenics’ JETREA® Gains First Asian Approval in Malaysia
JETREA® (ocriplasmin) has been approved for the treatment of adults with vitreomacular traction.
Tuesday, April 22, 2014
ThromboGenics’ JETREA® Receives Positive Common Drug Review in Canada
CDR provides formulary listing recommendations to Canada’s publicly funded drug plans.
Monday, December 30, 2013
ThromboGenics Appoints Dr David Guyer to its Board of Directors
Dr Guyer is currently the Co-Founder and Chief Executive Officer of Ophthotech Corporation.
Monday, December 23, 2013
ThromboGenics’ Founder Prof Desire Collen Retiring as Chairman
Dr Staf Van Reet appointed as new Chairman of the Board.
Monday, December 09, 2013
ThromboGenics’ JETREA® Available in Germany Public and Private Market
Company could receive a further €210 million in milestones plus significant royalties.
Friday, May 03, 2013
ThromboGenics Receives Positive CHMP Opinion for JETREA®
Positive opinion clears the way for the potential EMA approval of JETREA® as the first pharmacological option for the treatment of VMT, including when associated with macular hole of diameter less than or equal to 400 microns.
Wednesday, April 24, 2013
ThromboGenics’ JETREA® Granted EU Approval for VMT
EU approval of JETREA® triggers a €45 million milestone payment from Alcon.
Monday, April 15, 2013
ThromboGenics Announces Business Update and 2012 Full-Year Results
Transformational 2012 delivers euro 30 million in net profit.
Tuesday, March 19, 2013
Scientific News
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
New Diabetes Drug has Unexpected Side Effect
A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to new research.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Cannabis May Be Used to Treat Fractures
TAU researcher finds non-psychotropic compound in marijuana can help heal bone fissures.
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!